pharm edaily

[Kim Jinsoo, Edaily Reporter] SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company held an exclusive meeting with the Gates Foundation in line with Bill Gates’ visit to Korea to discuss ways to advance global health collaboration.

Key officials from SK bioscience and the Gates Foundation pose for a commemorative photo after a meeting.

The meeting was held on August 20 in Yeouido, Seoul, and attended by Trevor Mundel, President of Global Health of the Gates Foundation, along with other key foundation representatives, as well as Andrew Chey, Vice-Chairman of SK discovery, and Jaeyong Ahn, CEO of SK bioscience.

During the meeting, both organizations reaffirmed their long-standing partnership and commitment to working together on vaccine development and global public health projects. They also explored expanded cooperation in next-generation preventive medicines, with an emphasis on R&D for pandemic preparedness.

Since 2013, SK bioscience and the Gates Foundation have collaborated on multiple initiatives, including the development of typhoid and pediatric diarrhea vaccines and other antiviral preventive solutions, contributing to global public health. A notable milestone in their collaboration was the successful development and commercialization of SKYCovione in 2022, Korea’s first domestically developed COVID-19 vaccine. That year, Bill Gates and Trevor Mundel visited Korea to celebrate the achievement, meeting with Tony Chey, Chairman of SK Group, and Andrew Chey, Vice-Chairman of SK discovery.

SK bioscience remains committed to working with global partners to advance public health and expand equitable access to vaccines worldwide.